Meet with... Sanderling Ventures

Add this event to your calendar:
06/10/2016 12:30 06/10/2016 15:00 America/Toronto Meet with... Sanderling Ventures JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1 JLABS @ Toronto false DD/MM/YYYY

Meet with... Sanderling Ventures

JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1

October 06, 2016 from 12:30 PM to 15:00 PM (EST)

$10 - $35

Sanderling is investing in today's seeds for tomorrow's harvest; is your technology the next bumper crop?

Since 1979, Sanderling has been dedicated to building new biomedical companies, utilizing a unique approach of specialized investment focus, active managing and long term commitment. Sanderling has supported over 90 biomedical companies from very early stage start-ups, through commercial development. 



Investments are made at all stages with a focus on ground breaking early stage technologies that reduce costs in hospitals. Currently they are investing Sanderling VII which closed in 2015. Investment areas include:

  • Small molecule therapeutics
  • Biologics and vaccines
  • Drug delivery
  • Platform technologies
  • Medical devices
  • Diagnostics
  • Digital/eHealth

Sanderling Ventures Managing Director Timothy Mills will be in attendance to give an overview presentation about the company's key areas of interest. Following the presentation, don't miss this opportunity to introduce yourself to Timothy during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Sanderling will provide an intimate forum to discuss your company.

10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on September 8th.

Sanderling Ventures Participating Representative:
Timothy Mills | Managing Director, Sanderling Ventures
Timothy Mills has over twenty-five years of experience in biomedical research, corporate management and venture capital investing. Dr. Mills joined Sanderling as an Operating Partner in July 1998, was promoted to Managing Director in 2000 and currently serves as the Chairman of the Investment Committee. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. His active roles within Sanderling's portfolio companies include Chairman, CEO, Director, and management team member. Portfolio companies previously served include Stereotaxis (NASDAQ: STXS), Stentor, acquired by Royal Philips Electronics (NYSE: PHG, AEX: PHI), CardioNet (NASDAQ: BEAT), Taligen Therapeutics, acquired by Alexion Pharmaceuticals (NASDAQ: ALXN), Neomend, acquired by C.R. Bard (NYSE: BCR), Sotera Wireless and InfraReDx (acquired by Nipro Corporation). Currently, his roles also include Chairman of Torax Medical, Pulsar Vascular and AdMIRx. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific (NYSE: BSX) in 1997 for $1.3 billion. From July 1994 to July 1997, he was a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates. Before joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (NYSE: EW). Dr. Mills' previous academic appointments included Director of the Artificial Heart Program at the University of California, Irvine Medical Center and faculty member at the University of California, San Francisco Radiology Department. Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine. He also received a M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and a B.S. in Electrical Engineering from the University of Colorado, Boulder. In addition, he is an advisory board member of the University of Colorado Technology Transfer Office and a program faculty member of the Stanford University Biodesign program.
Connect with Timothy: Connect on LinkedIn

Presentation & Lunch
CA$ 35 | General Public
CA$ 50 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 5th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on September 8th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

JLABS @ Toronto
MaRS Centre, West Tower
661 University Ave, Suite 1300 [13th Floor]
Toronto, Ontario

JLABS @ Toronto

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit or follow @JNJInnovation.

Event contact

Related content